Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice.
about
Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells.Functions of Shp2 in cancer.Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.Mastocytosis: from a Molecular Point of View.Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy.
P2860
Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Oncogenic KIT-induced aggressi ...... r disease progression in mice.
@en
type
label
Oncogenic KIT-induced aggressi ...... r disease progression in mice.
@en
prefLabel
Oncogenic KIT-induced aggressi ...... r disease progression in mice.
@en
P2093
P2860
P356
P1433
P1476
Oncogenic KIT-induced aggressi ...... r disease progression in mice.
@en
P2093
Andrew W B Craig
Li-Fan Zeng
Namit Sharma
Reuben Kapur
Stephanie Everingham
Zhong-Yin Zhang
P2860
P304
P356
10.18632/ONCOTARGET.2177
P407
P577
2014-08-01T00:00:00Z